Cellebrite DI (NASDAQ:CLBT) Price Target Cut to $15.00 by Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan cut Cellebrite DI’s price target from $16 to $15 but kept its Overweight rating; the new target implies about 28% upside from the prior close.
• Analyst sentiment remains generally positive: four analysts rate the stock Buy and one rates it Sell, for a consensus Moderate Buy rating and $14.75 average target.
• Cellebrite’s quarterly revenue of $149 million topped estimates, as did reported EPS, but its $145 million–$150 million fourth-quarter revenue outlook is below the $151.6 million analyst consensus.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) had its price objective reduced by equities researchers at JPMorgan Chase & Co. from $16.00 to $15.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 27.98% from the company's previous close.

Other equities research analysts also recently issued research reports about the company. DA Davidson reissued a "buy" rating and set a $15.00 price target on shares of Cellebrite DI in a research report on Tuesday, September 15th. Weiss Ratings lowered Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, August 27th. Lake Street Capital reduced their price objective on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. Finally, Needham & Company LLC upped their price target on Cellebrite DI from $12.50 to $14.00 and gave the stock a "buy" rating in a report on Thursday. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.75.

Cellebrite DI Stock Performance

CLBT stock traded up $0.83 during midday trading on Friday, hitting $11.72. 2,965,446 shares of the stock were exchanged, compared to its average volume of 2,270,214. The stock's 50-day moving average price is $11.61 and its 200-day moving average price is $13.24. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of 53.29, a PEG ratio of 1.95 and a beta of 1.06. Cellebrite DI has a fifty-two week low of $9.58 and a fifty-two week high of $19.39.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported $0.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.08. Cellebrite DI had a net margin of 11.43% and a return on equity of 15.58%. The business had revenue of $149.02 million during the quarter, compared to analyst estimates of $145.83 million. Research analysts anticipate that Cellebrite DI will post 0.37 EPS for the current year.

Insider Transactions at Cellebrite DI

In related news, CMO David Gee sold 4,323 shares of Cellebrite DI stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $11.36, for a total value of $49,109.28. Following the completion of the transaction, the chief marketing officer directly owned 135,281 shares in the company, valued at approximately $1,536,792.16. This trade represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Hogan sold 25,299 shares of the business's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total value of $285,625.71. Following the completion of the sale, the insider directly owned 765,249 shares of the company's stock, valued at approximately $8,639,661.21. This represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 56,909 shares of company stock valued at $641,890 over the last ninety days. 5.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently bought and sold shares of the business. Weiss Asset Management LP lifted its holdings in Cellebrite DI by 3,485.3% in the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company's stock valued at $26,180,000 after acquiring an additional 1,846,851 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Cellebrite DI by 93.7% in the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company's stock valued at $44,529,000 after buying an additional 1,475,579 shares in the last quarter. Progeny 3 Inc. bought a new position in shares of Cellebrite DI in the first quarter valued at $15,546,000. Bank of New York Mellon Corp lifted its position in shares of Cellebrite DI by 107.0% during the 1st quarter. Bank of New York Mellon Corp now owns 1,333,563 shares of the company's stock valued at $18,376,000 after acquiring an additional 689,367 shares during the last quarter. Finally, Nine Ten Capital Management LLC lifted its position in shares of Cellebrite DI by 19.8% during the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company's stock valued at $60,251,000 after acquiring an additional 682,933 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI News Summary

Investors following CLBT have been watching these news items:

• Positive Sentiment: Q3 revenue was $149.0 million, above analysts’ $145.8 million forecast. EPS was $0.17; estimates varied by provider, with MarketBeat citing a lower $0.09 consensus while Zacks described results as in line. Cellebrite also reported 20% ARR growth, $26.7 million in net income, and a 31% trailing-twelve-month free-cash-flow margin. Third-quarter results
• Neutral Sentiment: Full-year 2026 revenue guidance of $553 million–$558 million brackets the $556.8 million consensus estimate, making the annual outlook broadly in line with expectations. Company results and guidance
• Negative Sentiment: Q4 revenue guidance of $145 million–$150 million is below the $151.6 million analyst consensus, a potential near-term headwind despite the strong quarter. Company results and guidance

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company's offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.